(MENAFN- GetNews)
DelveInsight's
“Pulmonary Hypertension associated with Interstitial Lung disease market Insights, Epidemiology, and Market Forecast – 2034”
report delivers an in-depth understanding of Pulmonary Hypertension associated with Interstitial Lung Disease, historical and forecasted epidemiology, as well as the Pulmonary Hypertension associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The
Pulmonary Hypertension associated with Interstitial Lung Disease Market
is an evolving segment of the global healthcare landscape, driven by the increasing prevalence of the disorder and the continuous development of innovative treatment options. The Pulmonary Hypertension associated with Interstitial Lung Disease market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Pulmonary Hypertension associated with Interstitial Lung Disease Market with DelveInsight's In-Depth Report @
Pulmonary Hypertension associated with Interstitial Lung Disease Market Size
Key Takeaways from the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report
In October 2024:- Pulmovant Inc.- A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease. This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
In October 2024:- Liquidia Technologies Inc.- This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population; also evaluate the steady-state pharmacokinetics (PK) of L606 as compared to Tyvaso, effects on exercise ability, quality of life, and treatment satisfaction with L606.
In October 2024:- Bayer- The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g. disturbed breathing) and outcome of pulmonary hypertension associated with lung fibrosis. Patients living with pulmonary hypertension associated with interstitial lung disease have a risk of increased number of hospitalisations because of worsening of their condition. Until now there is no approved medication for this disease.
In 2023, the total diagnosed prevalent cases of PH-ILD were nearly 172 thousand in the 7MM, which are expected to rise by 2034.
Among 7MM, the United States had the highest diagnosed prevalent cases of PH-ILD with 92 thousand cases in 2023.
EU4 and the UK countries accounted for 58 thousand diagnosed prevalent cases of PH-ILD in 2023, and is projected to increase by 2034. In 2023, with 14 thousand cases, Germany accounted for the highest number of diagnosed prevalent cases of PH-ILD, followed by the UK (13 thousand cases). On the other hand, Spain had the lowest and equal number of diagnosed prevalent population as approximately 9 thousand cases in 2023.
The leading Pulmonary Hypertension associated with Interstitial Lung Disease Companies such as United Therapeutics Corp, Insmed Incorporated, Bellerophon Therapeutics, and others.
Promising Pulmonary Hypertension associated with Interstitial Lung Disease Therapies such as Treprostinil Palmitil Inhalation Powder, Riociguat (Adempas, BAY63-2521), Mosliciguat, Mirivadelgat , and others.
Stay ahead in the Pulmonary Hypertension associated with Interstitial Lung Disease Therapeutics Market with DelveInsight's Strategic Report @ Pulmonary Hypertension associated with Interstitial Lung Disease Market Outlook
Pulmonary Hypertension associated with Interstitial Lung Disease Epidemiology Segmentation in the 7MM
Pulmonary Hypertension associated with Interstitial Lung Disease Diagnosed prevalent cases
Pulmonary Hypertension associated with Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
Pulmonary Hypertension associated with Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
Pulmonary Hypertension associated with Interstitial Lung Disease Diagnosed Prevalent Cases
Download the report to understand which factors are driving Pulmonary Hypertension associated with Interstitial Lung Disease epidemiology trends @ Pulmonary Hypertension associated with Interstitial Lung Disease Prevalence
Pulmonary Hypertension associated with Interstitial Lung Disease Marketed Drugs
TYVASO/TYVASO DPI (treprostinil): United Therapeutics Corp.
TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are both prostacyclin mimetics indicated for the treatment of PH-ILD [WHO Group 3]. TYVASO or TYVASO DPI can improve the ability to exercise. In December 2020, the FDA and in March 2024, the EMA granted ODD for treprostinil to treat IPF. Currently, the drug is in its late developmental phases for IPF.
Pulmonary Hypertension associated with Interstitial Lung Disease Emerging Drugs
Treprostinil Palmitil: Insmed Incorporated
Treprostinil palmitil is a long-acting pulmonary vasodilator prodrug of treprostinil (TRE). It offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
INOpulse: Bellerophon Therapeutics
INOpulse drug-device combination therapy under the developmental pipeline of Bellerophon Therapeutics for the treatment of patients with PH-ILD. The device is designed to be portable for ambulatory patients daily inside or outside their homes. INOpulse delivery system is programmed to adjust automatically based on breathing patterns and delivers a constant and appropriate dose independent of the patient's activity.
Get In-Depth Knowledge on Pulmonary Hypertension associated with Interstitial Lung Disease Market Trends and Forecasts with DelveInsight @ Pulmonary Hypertension associated with Interstitial Lung Disease Treatment Market
Pulmonary Hypertension associated with Interstitial Lung Disease Market Outlook
There is no standard approach to assessing patients' risk of PH. Currently, two formulations of inhaled treprostinil have obtained approval from the US FDA in April 2023 and May 2024 for TYVASO (inhalation solution) and TYVASO DPI (inhalation powder), respectively. The underlying lung disease is optimally treated with supplemental long-term oxygen therapy, diuretics, anticoagulants, and pulmonary rehabilitation. PH-specific therapy like prostanoids (FLOLAN, treprostinil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan), and phosphodiesterase inhibitors (sildenafil) are used off-label to manage blood pressure.
Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights
The appearance of increased pulmonary pressures is uniformly a harbinger of poor outcomes, and so is the case in PH-ILD. Advances in therapeutic options have led to an urgency to look for PH in ILD patients. In the usual care of ILD patients, specific symptoms, physical exam results, and laboratory and imaging findings can point to additional testing, such asechocardiography. However, further studies are needed to overcome several unmet needs on the therapeutic and diagnostic front
Unlock Strategic Insights with DelveInsight's Comprehensive Pulmonary Hypertension associated with Interstitial Lung Disease Market Report @ Pulmonary Hypertension associated with Interstitial Lung Disease Market Drivers and Barriers
Scope of the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report
Coverage- 7MM
Pulmonary Hypertension associated with Interstitial Lung Disease Companies- United Therapeutics Corp, Insmed Incorporated, Bellerophon Therapeutics, and others.
Pulmonary Hypertension associated with Interstitial Lung Disease Therapies- Treprostinil Palmitil Inhalation Powder, Riociguat (Adempas, BAY63-2521), Mosliciguat, Mirivadelgat, and others.
Pulmonary Hypertension associated with Interstitial Lung Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Pulmonary Hypertension associated with Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Pulmonary Hypertension associated with Interstitial Lung Disease Market Access and Reimbursement
Table of Content
1: Key Insights
2: Report Introduction
3: Pulmonary Hypertension Associated with Interstitial Lung Disease Market Overview at a Glance
4: Epidemiology and Market Methodology
5: Executive Summary
6: Key Events
7: Disease Background and Overview
8: Epidemiology and Patient Population of PH-ILD
9: Patient Journey
10: Marketed drugs
11: Emerging Drugs
12. Key Cross Competition
13: Unmet Needs
14: SWOT Analysis
15: Key Opinion Leaders' Views
16: Reimbursement and Market Access
17: Appendix
18: DelveInsight Capabilities
19: Disclaimer
20: About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
MENAFN06112024003238003268ID1108859144
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.